# A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

> **NCT04626635** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 933 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** REGN7075
- **DRUG:** Cemiplimab
- **DRUG:** Platinum-based doublet chemotherapy
- **DRUG:** Bevacizumab
- **DRUG:** Trifluridine-tipiracil

## Key facts

- **NCT ID:** NCT04626635
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2026-08-19
- **Final completion:** 2027-04-07
- **Target enrollment:** 933 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626635, "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04626635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*